



Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264
Plot No. 104, Ravindra Co Operative Society, Guttala Begumpet,
Kakateeya Hills, Hyderabad - 500 081. Telangana, INDIA. Tel : 040 - 23741585
E-mail : admin.hyd@vistapharmaceuticals.com @www.vistapharmaceuticals.com

To
The Manager
BSE Limited
P. J. Towers, Dalal Street,
Mumbai – 400001.

Date: 14.11.2024

Dear Sir/Madam,



Subject: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Issue of World Health Organisation (WHO) G.M.P. Certificate.

Pursuant to the Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (“Listing Regulations”), we wish to inform you that “Issue of World Health Organisation (WHO) G.M.P. Certificate” vide Letter No. 150107/TS/2024 dated November 08, 2024 from Government of Telangana, Department of Drugs Control Administration. The required information in compliance with SEBI Circular ref. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023, pertaining to the above license are provided in Annexure A. The aforesaid information is also being placed on the website of the Company at www.vistapharmaceuticals.com. We request you to take the same on your record.

This is for the information and records of the Exchange, please.

Thanking You,

Yours faithfully,
For Vista Pharmaceuticals Limited

Dhananjaya Alli
Executive Director
(DIN: 00610909)



Vista Pharmaceuticals Ltd



CIN : L24239TG1991PLC012264
Plot No. 104, Ravindra Co Operative Society, Guttala Begumpet,
Kakateeya Hills, Hyderabad - 500 081. Telangana, INDIA. Tel : 040 - 23741585
E-mail : admin.hyd@vistapharmaceuticals.com www.vistapharmaceuticals.com

Annexure-A

Disclosure under Para B of Part A of Schedule III to the Regulation 30 of the SEBI Listing Regulations:

S. No.	Items of Disclosure	Description
1.	Name of the Regulatory or Licensing Authority	Government of Telangana, Department of Drugs Control Administration (DCA), Telangana State
2.	Brief details of the approval/license obtained	License to Manufacture for exports of Sulfamethoxazole and Trimethoprim Tablets IP/USP
3.	Impact/relevance of such approval/license	Grant of License to Manufacture Sulfamethoxazole and Trimethoprim Tablets IP/USP for exports for ROW(Rest of the World) Market purpose
4.	Period for which such approval/license is/was valid	valid upto 31/12/2027

For Vista Pharmaceuticals Limited

Dhananjaya Alli
Executive Director
(DIN: 00610909)